Inclusion Criteria:

1. Capable of giving written informed consent

2. Females of non-childbearing potential, 18 years or older with ovarian cancer

3. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or
persistent ovarian cancer

4. Histologically or cytologically confirmed diagnosis of PET-positive recurrent or
persistent uterine or gastro-oesophageal tumors (these tumor types will only be
included if there is poor enrollment of patients with ovarian cancer)

5. Disease at least 2 cm suitable for assessment by imaging

6. Performance Status score of 0, 1 or 2 according to the Eastern Cooperative Oncology
Group scale

7. Adequate organ systems function

Exclusion Criteria:

1. Chemotherapy, radiotherapy, or immunotherapy within 28 days prior to the first dose
of GSK2141795

2. Use of an investigational anti-cancer drug within 28 days or five half-lives,
whichever is shorter, prior to the first dose of GSK2141795

3. Current use of a prohibited medication

4. Anticoagulants at therapeutic doses are permitted only after consultation with the
GSK Medical Monitor

5. Presence of active gastrointestinal disease or other condition that could affect
gastrointestinal absorption

6. Any major surgery within the last four weeks of screening

7. Unresolved toxicity greater than or equal to Grade 2 from previous anti-cancer
therapy

8. Previously diagnosed diabetes mellitus

9. Current use of oral corticosteroids, with the exception of inhaled or topical
corticosteroids

10. Any serious or unstable pre-existing medical, psychiatric, or other condition

11. Symptomatic or untreated CNS metastases or leptomeningeal involvement

12. Evidence of severe or uncontrolled systemic diseases

13. QTc interval ≥ 470 msecs

14. Other clinically significant ECG abnormalities

15. History of myocardial infarction, acute coronary syndromes

16. Class III or IV heart failure

17. Pregnant or Lactating patients

18. History of hepatitis B or C or HIV